Psyence Biomedical Ltd. · NASDAQ:PBM
Psyence Biomedical — Investor Presentation (May 2025)
41 slides from Psyence Biomedical's investor presentation, May 15, 2025
Slide 1: Investor Presentation
Investor Presentation Nasdaq: PBM May 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation (“Presentation”) is being issued by Psyence Biomedical Ltd. (the “Company” or “Psyence BioMed”) for information purposes only. The content of this Presentation has not been approved by any There are numerous risks and uncertainties that may cause actual r
Slide 3: Forward Looking Statements: Industry and Market Data
Forward Looking Statements Industry and Market Data This Presentation has been prepared by Psyence BioMed and includes market data and other statistical information from third-party sources. Although Psyence BioMed believes these third-party sources are reliable as of their respective dates, neither
Slide 4: Risk Factors Relating to Psyence BioMed's Business
Risk Factors Relating to Psyence BioMed’s Business Psyence BioMed is a clinical-stage biotechnology company with a limited operating history and The results of clinical trials are open to differing interpretations. Psyence BioMed may be subject to significant accumulated losses. We expect continued
Slide 5: Strategic Outlook
STRATEGIC OUTLOOK THE COMPANY & GLOBAL VALUE PROPOSITION OPERATIONS SCIENTIFIC CREDIBILITY / CLINICAL PIPELINE ADDRESSABLE MARKET: PALLIATIVE CARE / AUD & SUD REGULATORY ENGAGEMENT LEADERSHIP DEPTH STRATEGIC ALLIANCES CONTACT US
Slide 6: Mission
MISSION To advance a portfolio of nature-derived, evidence-based therapeutics targeting unmet mental health needs in palliative care, addiction, and related conditions, through a fully integrated biotechnology platform with in-house capabilities in cultivation, manufacturing, and clinical developmen
Slide 7: Organizational Alliance
Organizational Alliance Psyence BioMed owns a strategic equity stake in PsyLabs. Together, they form a fully integrated biotechnology platform that connects clinical development, GMP-certified manufacturing, and commercialization – advancing evidence-based, nature-derived psychedelic therapies from
Slide 8: Company Highlights
Company Highlights Phase IIb program, 25mg psilocybin in conjunction with proprietary psychotherapy, being evaluated for Adjustment Disorder in cancer in the Palliative Care context Leveraging benefits of nature-derived psilocybin, including potential synergistic effects of similar acting molecules
Slide 9: Value Proposition
Value Proposition Psyence BioMed is the only Nasdaq-listed biotech company focused on nature- derived psychedelics with global commercialization potential for psilocybin and ibogaine, giving it a distinct strategic edge with multiple advantages, including: • First-Mover Advantage • Global Commercial
Slide 10: Accelerating Psychedelics M&A and Growing Institutional Investor Interest
Accelerating Psychedelics M&A and Growing Institutional Investor Interest Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 10
Slide 11: Aligned with Positive 2024 - 2025 Industry Trends
Aligned with Positive 2024 - 2025 Industry Trends Mid-Stage, De-Risked Clinical Focus Advancing to Phase IIb, Psyence BioMed is firmly positioned in the mid-stage space favored by investors for its more defined regulatory pathway and lower risk profile. Big Pharma & Institutional Momentum Deals like
Slide 12: Development Portfolio
DEVELOPMENT PORTFOLIO Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 12
Slide 13: Anticipated Developmental Pathway to Approval
Anticipated Developmental Pathway to Approval1 Transition to Southern Star Research (CRO) Top Line Results 4 6 FDA Pre-IND Feedback Two trial sites Received selected Q2 2023 Q1 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 H1 2026 H2 2026 HREC approved Phase IIb study in Adjustment Disorder (announced March
Slide 14: PBM Development Portfolio
PBM Development Portfolio Projected Upcoming Pre-clinical Phase I Phase II Phase III Milestones Adjustment Disorder Phase IIb First patient enrolled Q2 2025 Psilocybin 25mg Alcohol Use Disorder/ Substance Use Protocol to be developed by Disorder Q4 2025 Psilocybin 25mg Undisclosed Evaluation of pre-
Slide 15: PEX010: Phase IIb Trial Design
PEX010: Phase IIb Trial Design Study Design: Cohort 1 Cohort 2 Cohort 3 A randomized, double-blind, low-dose comparator- 25mg PEX010 10mg PEX010 1mg PEX010 controlled Phase IIb study to investigate the efficacy and 29 subjects 29 subjects 29 subjects safety of psilocybin-assisted psychotherapy (PAP)
Slide 16: PEX010: Australia Clinical Trial Phase IIb (Updated)
PEX010: Australia Clinical Trial Phase IIb (Updated) Psyence BioMed’s clinical trial program is focused on assessing the safety and efficacy of psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder* associated with a cancer diagnosis in the Palliative Care context. Overview Prod
Slide 17: Prior Proof-of-Concept Studies Provide Encouraging Rationale for Phase IIb
Prior Proof-of-Concept Studies Provide Encouraging Rationale for Upcoming Indication in Phase IIb At the 6-month follow-up, these changes were At the 6.5-month follow-up, psilocybin was sustained, with about 80% of participants associated with enduring anxiolytic and continuing to show clinically si
Slide 18: Psyence BioMed's Intellectual Property within Drug development
Psyence BioMed’s Intellectual Property within Drug development Our intellectual property strategy is built around the following objectives: Ensuring that we have freedom to operate (free of infringing third party patents) to pursue our commercial objectives in our key markets • We conduct ongoing pa
Slide 19: Investing in Growth Markets: Palliative & Addiction Disorder Therapeutics
INVESTING IN GROWTH MARKETS: PALLIATIVE & ADDICTION DISORDER THERAPEUTICS Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 19
Slide 20: Palliative Care is NOT End-of-Life (Hospice) Care
Palliative Care is*: Palliative Care is NOT • Specialized medical care for people living with a life limiting End-of-Life (Hospice) illness, such as cancer or heart failure. Care • Patients in Palliative Care may continue to receive treatment In Palliative Care, a person does as well as care intende
Slide 21: The Global Palliative Care Market is Large with a Robust Projected CAGR
The Global Palliative Care Market is Large with a Robust Projected CAGR Other Disease $14.7B* Projected Global Palliative Care Market $23.3B with 9.1% CAGR (2032)* Cancer Cancer = ~37% of Total PC Market $8.6B* *Source: https://www.globenewswire.com/news-release/2024/10/15/2963268/0/en/Palliative-Ca
Slide 22: WHO Study: Worldwide, 56.8 Million People Require Palliative Care
WHO Study: Worldwide, 56.8 Million People Require Palliative Care Patients Requiring Palliative Care, Globally (millions) 34% of patients requiring palliative care – 19.3 million people – have received a serious 3.9 cancer diagnosis 2 3.2 According to the WHO, “The 5.9 21.9 global need for palliativ
Slide 23: Alcohol Use Disorder (AUD) & Substance Use Disorders (SUDs)
ALCOHOL USE DISORDER (AUD) & SUBSTANCE USE DISORDERS (SUDS) Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 23
Slide 24: AUD and Other SUDs: A Global Burden
AUD and Other SUDs: A Global Burden *A 2024 WHO report urges faster global action to meet Sustainable Development Goal 3.5 by 2030, focusing on reducing alcohol and drug use and improving access to treatment for substance use disorders. • 48.5 million Americans aged 12 and older (16.7%) experienced
Slide 25: Alcohol abuse and dependence have the widest treatment gap
Alcohol is a Leading Risk Factor in the Overall Disease Burden Globally1 80% of adults drink Alcohol abuse and 339M alcohol2 dependence have the widest treatment gap 15% of adults in these among all mental 50M countries are “at risk” health disorders of AUD3,4 Drug treatment Only 1% of drinkers effi
Slide 26: Recent Academic Studies for Psilocybin in SUDs and Patients with Cancer
Recent Academic Studies Provide Encouraging Scientific Rationale for Continued Development of Psilocybin for SUDs and Patients with Cancer (2024 – 2025) A screenshot of a computer A screenshot of a website Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 26
Slide 27: Adjustment Disorder
ADJUSTMENT DISORDER Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 27
Slide 28: Adjustment Disorder (AjD)
Adjustment Disorder (AjD) A global survey of psychiatrists by the WHO revealed1: • AjD plays an enormous role in healthcare utilization • AjD ranked 7th among 44 psychiatric categories2 they managed at least once a week in their practice • A second global survey of clinical psychiatrists ranked AjD
Slide 29: Strategic Alliances
STRATEGIC ALLIANCES Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 29
Slide 30: Strategic alliance with PsyLabs is a critical pillar of competitive advantage
Psyence BioMed’s strategic alliance with PsyLabs is a critical pillar of its competitive advantage and long-term value proposition. Here’s why the relationship is so important: • Reliable Supply of Natural Psychedelics: Exclusive partnership with federally licensed PsyLabs secures pharmaceutical-gra
Slide 31: Ibogaine
IBOGAINE Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 31
Slide 32: Emerging Leader in Ibogaine-Based Addiction Therapeutics
Emerging Leader in Ibogaine- Based Addiction Therapeutics Psyence BioMed’s strategic alliance with PsyLabs is central to its leadership in ibogaine-based addiction therapeutics. Through this partnership, we have secured worldwide rights of first refusal to nature- derived, pharmaceutical-grade iboga
Slide 33: Ibogaine: A Novel Opportunity in Mental Health Treatment
Ibogaine: A Novel Opportunity in Mental Health Treatment A 2024 Stanford study found that a single dose of ibogaine, given to 30 U.S. Special Operations veterans with TBI and PTSD, led to lasting improvements in PTSD, depression, anxiety, and functioning – with no serious side effects. These finding
Slide 34: Market Segmentation and Competitors
MARKET SEGMENTATION AND COMPETITORS Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 34
Slide 35: Significant Unexplored White Space in Nature Derived Psilocybin & Ibogaine
Significant Unexplored White Space Exists in the Area of Nature Derived Psilocybin & Ibogaine Nature derived Ayahuasca, Ibogaine Psilocybin Other Psilocybin psychedelics MDMA, Ketamine, LSD Psilocybin Synthetic Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 35
Slide 36: Value Driven Opportunity Versus Peer Companies
Psyence BioMed Represents a Value Driven Opportunity Versus Peer Companies (1) Company Ticker Market Cap Business Descriptions GH Research NasdaqGM: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Res
Slide 37: Meet the Team
MEET THE TEAM Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 37
Slide 38: Psyence BioMedical Ltd Management Team
Psyence BioMedical Ltd Management Team Proven Track Record in Innovation with Extensive Pharma Development Experience Dr. Neil Maresky Jody Aufrichtig Warwick Corden-Lloyd CEO Executive Chairman Chief Financial Officer Trained MD in Emergency Medicine and Family Practice Chartered Accountant (ex EY)
Slide 39: Psyence BioMed Board of Directors
Psyence BioMed Board of Directors Proven Track Record in Innovation with Extensive Operating Experience Dr. Neil Maresky Jody Aufrichtig Marc Balkin CEO Executive Chairman Board Member Trained MD in Emergency Medicine and Family Practice Chartered Accountant (ex EY) with 25 years private equity expe
Slide 40: Psyence BioMed Scientific Advisory Board
Psyence BioMed Scientific Advisory Board Proven Track Record in Innovation with Extensive Operating Experience Albert Garcia-Romeu, Ph.D Dr. Dan Stein Chair, Scientific Advisory Board SAB member Professor and Chair of the Dept of Psychiatry and Mental Johns Hopkins University School of Medicine Heal
Slide 41: Thank You / Contact
THANK YOU CONTACT General inquiries — info@psyencebiomed.com Investor inquiries — ir@psyencebiomed.com Tel: +1-416-477-1708 Address: 121 Richmond Street West, Penthouse Suite, 1300, Toronto ON M5H2K1, Canada Psyence BioMedical Ltd. / Healing Minds with Science . Changing Lives with Nature 41
Psyence Biomedical — Investor Presentation (May 2025) on 6ix